To assess whether the utilisation of a motor response of <3 V during Stage 1 sacral neuromodulation (SNM) results in better clinical outcomes compared to >4 V in patients with overactive bladder (OAB) or urinary retention symptoms.
Results
The mean (SD) follow-up was 116.3 (30.3) months in Group A and 112 (34.6) months in Group B (P < 0.354); 150.5 (20.4) months in Group C and 145.8 (17.2) months in Group D (P < 0.38). Successful conversion of Stage 1 to Stage 2 showed statistically significant improvement for both <3-V groups (Groups A and C). Group A had a 93.5% (174/186) conversion rate vs 72.3% (110/152) in Group B for OAB symptoms (P < 0.001). Group C had a 94% (34/36) conversion rate vs 70% (21/30) in Group D (P < 0.017). Defined as a ≥50% reduction in frequency, urgency, urgency incontinence and nocturia, and UDI-6 and IIQ-7 scores, the success rate for Group A was 82.1% (143/174) and for Group B was 63% (69/110) (P < 0.001). The mean battery life improved in both <3-V cohorts (P < 0.001). Annual reprogramming sessions were reduced in Group A and Group C (P < 0.001). Subset analysis of variance showed no statistical improvement in most patient outcomes when 1-V subjects were compared to 2-and 3-V cohorts. However, 32% of 1-V patients (P < 0.001) noted the onset of severe pelvic/perirectal pain and big toe plantar flexion movement with small increments in voltage (0.1-0.2 V) during reprogramming. Only 7% of 2-V and 1% of 3-V patients experienced this complication.
Introduction
Sacral neuromodulation (SNM) is a well-studied, minimally invasive, third-tier surgical therapy for women with medically recalcitrant overactive bladder (OAB) or urinary retention symptoms [1] . A panoramic view of the procedure's evolution reveals significant technological improvements in hardware and surgical implantation. In early procedures, the lead was secured to the lumbodorsal fascia but was replaced with a self-retaining model in 2002 [2] . A two-staged approach featuring placement of the permanent lead with an external, portable impulse generator was another improvement over percutaneous testing, with a temporary, office-placed, 2-3 day lead [3] . In 2006, the InterStim â II (Medtronic Inc., Minneapolis, MN, USA) implantable pulse generator (IPG) model 3058 was introduced, with a 37% decrease in displaced volume and 50% reduction in weight (22 vs 42 g), when compared to the original InterStim I footprint (model 3023). Product lifespan for the InterStim II was unfortunately reduced to 3-5 years from the original model's 5-7 years, but new software upgrades now allow for data tracking and patient self-reprogramming options [4] . Further improvements in the InterStim II include Federal Drug Administration (FDA) approval for 1.5-T MRI head imaging (see Medtronic MRI guidelines). The self-contained tined lead is now available in a longer 43-cm length, for application in larger-frame patients and for non-FDA approved pudendal neuromodulation [5, 6] . Improvements are not limited to software/hardware innovations. An alteration in Stage 1 SNM approach and technique was brought to light during a review of the fundamentals of electrophysiological theory, namely that the lower the amount of voltage used to stimulate a motor response, the higher the potential for improved stimulation of the intended muscle unit [7, 8] . The Medtronic Corporation has never heralded any recommendations about the amount of voltage for a motor response, and this element of adjustment has not been explored in the SNM literature [1] [2] [3] [4] [5] . However, we have an extensive 15-year experience utilising our method of a <3-V motor response in women with OAB symptoms and urinary retention that is described in the present study.
Patients and Methods
An observational, retrospective, double cohort review was conducted of 339 female patients who had experienced medically recalcitrant OAB symptoms or non-obstructive urinary retention. Between September 2001 and September 2014, four cohorts underwent successful Stage 1 to Stage 2 SNM placement. Group A included 174 women who underwent differential quadripolar tined lead motor response (bellows and plantar flexion) with one or more leads at ≤3 V, and Group B evaluated 110 women who underwent the same protocol with all lead motor response ≥4 V for medically recalcitrant OAB symptoms (frequency, urgency, urgency incontinence, nocturia, or urinary retention). Group C comprised 33 women with one or more motor response at ≤3 V, and Group D identified 22 women treated with a motor response at ≥4 V for non-obstructive urinary retention symptoms. Stage 1 and Stage 2 surgeries were performed between January 2002 and January 2013 under a general anaesthetic, with a motor response void of all patient verbal sensory input.
All 339 patients underwent similar perioperative diagnostic evaluations including: a complete history and physical examination, urine analysis, urine culture and cytology (as indicated), 3-day voiding diary (preoperative and at 2016 follow-up), multichannel video-urodynamics (including uroflowmetry), office flexible cystoscopy, post-void residual urine (PVR) via straight catheterisation or ultrasonographically determined, Urogenital Distress Inventory-6 (UDI-6; score range 0-100), Incontinence Impact Questionnaire-7 (IIQ-7; score range 0-100), and Patient Global Impression of Improvement Questionnaire (PGI-I; score range 1-7) [9] , all pre-and postoperatively, and at the 2016 follow-up as clinically indicated. The numerical voltage values for all four lead electrodes 0, 1, 2, 3 at surgery and adverse events were tracked. Internal Review Board permission for this study was both requested and received in 2016. No funding was requested or received from any source. Successful lead placement was determined by having two or more leads presenting with S 3 bellows (levator ani contraction) and ipsilateral big toe plantar flexion. 3-day voiding diaries were used to objectively assess patient success (defined as a 50% reduction in mean frequency, urgency, urgency incontinence and nocturia; or a return to normal voiding frequency of <8 voids/24 h day/night cycle). Patients with urinary retention needed to have consistent PVRs either through straight catheterisation or ultrasonographically determined values of <100 mL. Preoperative and follow-up maximum urinary flow rate (Q max ) was also determined as an accessory qualitative measure.
All adverse events were included during each of the four cohorts' ongoing evaluations. These included events related to either Stage 1 or 2 surgery, therapy, device, or implant site. Battery acquiescence and replacement are a necessary part of this therapy and were not included as an adverse event. Follow-up examinations were performed by independent, board certified physicians with experience in SNM and its programming. For inclusion in the study, patients needed a minimum of 3 years' follow-up.
Data were analysed using the IBM Statistical Package for the Social Sciences (SPSS â ) version 19 (SPSS Inc., IBM Corp., Armonk, NY, USA). Categorical data were analysed using Fisher's exact test and Pearson's chi-squared. Continuous data were analysed using Student's independent samples t-test and Mann-Whitney U-test for non-normal data. Comparisons of pre-and post-measures were conducted using repeated measures ANOVA. The data were analysed using a multivariate ANOVA (MANOVA), in which the differences between voltage groups (1, 2, and 3 V), as well as the change from pre-and post-measures (time) were compared. A voltage by time interaction was also examined. Paired comparisons to examine differences between groups and times were also conducted. For all factors a P ≤ 0.05 was deemed statistically significant (Video S1).
Surgical Procedure
The patient was brought to the operating room after surgical antibiotic prophylaxis and placed onto a Jackson orthopaedic table. We do not embrace the sensory means of motor response and positional lead placement, so the patient was given a general endotracheal anaesthetic without paralysing agents and turned 180°to the prone position. The Jackson table has no centre 'I beam', so table obstruction during fluoroscopy is obviated. We used a two-staged approach instead of an initial percutaneous nerve evaluation technique. With a surgical marking pen and radio-opaque 30.5-cm (12-inch) ruler guidance, the C-arm outlined the sacrospinous processes in the midline sacrum down to the coccyx. A vertical line was drawn, connecting both right and left pelvic brim sciatic notches. Next, both S 3 foramina (medial side) had a tangential line drawn away from the midline sacrospinous line. This line segment connoted the aspired positions of both sides of the S 3 nerve. A 12.7-cm (5-inch) bored needle with an attached white test stimulation cable was set at 3 V in Groups A and C, and at 6 V in Groups B and D. We used an electrically active needle to immediately discern a successful motor response of the levator ani (bellows) and ipsilateral big toe (plantar flexion), confirming S 3 placement. Once both were obtained, the procedure was completed by bringing the end of the tined lead and external connection through the ipsilateral buttock pocket to the counter-lateral posterior superior iliac crest area, as per Medtronic recommendations. We used 2-0 nylon suture with an air knot to secure the external connecting wire to the external impulse generator.
Results
The mean (SD) follow-up in months was: 116. (Table 1) showed statistically significant improvement for both <3-V groups (Group A and C). Group A had a 93.5% (174/186) conversion rate vs 72.3% (110/152) in Group B for OAB symptoms (P < 0.001). Group C had a 94% (34/36) conversion rate compared to 70% (21/30) in Group D for urinary retention (P < 0.017). The success rate, with a definition of ≥50% reduction in frequency, urgency, urgency incontinence, nocturia, and UDI-6 and IIQ-7, for Group A was 82.1% (143/174) vs 63% (69/110) for Group B (P < 0.001). The success rate for urinary retention was not significantly improved from Group C at 85% (28/33) compared to Group D at 72.9% (16/22) (P = 0.32). However, the study enrolment number (n) needed to achieve statistical significance (notwithstanding Group C's 12.1% improvement over Group D) would have been n = 99 for Group C and n = 66 for Group D, or a total of 165 participants. The mean (SD) PGI-I scores were significantly different between Group A, at 2.34 (0.76) and Group B at 1. 2) vs to 57.18 (6.67) months, respectively (P < 0.001). Battery duration measurements were taken from the InterStim II IPG exclusively. All InterStim I IPGs' historical data were excluded, so as not to confuse battery duration amongst the two types of IPGs, as the latter has not been available since 2008. Annual reprogramming sessions were reduced in Group A by a mean (SD) of 1.13 (0.81) compared to Group B at 1.86 (1.24) (P < 0.001). Tables 2 and 3 show the percentage improvement in multiple voiding parameters in which the ≤3-V Groups A and C outperformed their comparison group. haematomas secondary to accidents). There were no significant differences between the four cohorts for body mass index, anaesthetic risk factors, postoperative PVR, postoperative Q max , or duration of follow-up. Our power for the MANOVA was 0.80, indicating adequate sample size to show a significant multivariate voltage effect if there were such an effect. There was an overall significant time difference between pre-and post-measures when using MANOVA (Wilks' Lambda = 636.3, d.f. = 7, P < 0.001). The interaction MANOVA for voltage by time was not significant (P = 0.573).
A multivariate comparison was performed to see if either the 1-V, vs 2-V and 3-V patients (combined) in Group A outperformed the other with regard to all data points discussed in Table 1 . To ascertain these results, a MANOVA analysis was performed (Fig. 1) . The overall MANOVA for the voltage effect was not significant (Wilks' Lambda = 1.34, d.f. = 14, P = 0.180). The univariate ANOVA analysis indicated that there were three significant differences between the motor response voltage subgroups with levels of 1-V compared to both 2-and 3-V with the complex of outcome variables as statistically depicted in Table 5 . The measures that showed the most statistically significant effects were for the 1-V cohort pertaining to PVR (P < 0.032) and postoperative nocturia (P < 0.043). However, Table 5 notes during patient self-reprogramming increased pelvic/perirectal pain and big toe movement with small incremental voltage increments of 0.1-0.2 V: 32% (23/73) in the 1-V cohort, 7% in 2-V patients, and 1% in 3-V patients (P < 0.001). Table 6 is a comparison of our data with three selected study results from important multi-institutional SNM studies for OAB symptoms [10] [11] [12] . Parameters include follow-up (months), Stage 1 to Stage 2 conversion rates (%), success rates (%), pre-to postoperative frequency, pre-to postoperative urgency, adverse events (%), and explant rate (%). Quality of life measurements (PGI-I) and voiding questionnaires were not used, not comparable, and not included in the analysis. All similar data were compared between the studies, with percentage improvement the determining factor or raw data taken at face value.
Discussion
During my physician training for SNM therapy in 2001, Medtronic Inc. did not recommend any specific analogue voltage levels for attainment of an S 3 motor response. A Medtronic representative was present at every Stage 1 SNM procedure. He or she would apply an arbitrary voltage between 6 and 8 V to stimulate the bellows (levator ani contraction) and elicit brisk plantar flexion of the big toe, demonstrating the criteria for tined lead activation. This method may promptly identify the S 3 nerve and may even minimise operative time and the patient's anaesthetic. However, between 2001 and 2015, there was no conjecture that a particular voltage would affect improved patient outcomes during a Stage 1 SNM motor response trial [7, 8] . It is of paramount importance to understand that every Stage 1 SNM is an electromyography (EMG) study in which a specific voltage is applied through a needle to the S 3 nerve to stimulate a motor contractile response. All EMGs should attempt motor stimulation response at the lowest possible voltage, as this may help locate a needle/tined lead position inherently closer in proximity to the nerve to be studied, theoretically with more congruent surface area between the nerve and tined lead, whilst optimising utilisation and elongating battery life (private communication with Dr John E. Hall, PhD, editor of Guyton and Hall Medical Physiology, 2015). We speculated that a successful lower voltage motor response at 3, 2 or 1 V may impart statistically significant improvements. Our statistical analysis may encourage practitioners to employ this straightforward technical modification during Stage 1 SNM. In our present study of >330 patients with either OAB or urinary retention, most voiding parameters improved (P < 0.05) by up to 40% when motor response was performed at ≤3 V. Stage 1 to Stage 2 conversion rates for both OAB and urinary retention were 94% (Table 1 ), a marked improvement over recent studies reporting a 35.4%, 49.1%, and 63.2% conversion rate [10, [13] [14] [15] [16] [17] . Success rates are defined as a ≥50% improvement in voiding parameters for Medicare recipients and serve as an international standard. Peeters et al. [10] relate a success rate of 70% (Table 6 ) in their 2014 study of patients with OAB and urinary retention, with 217 patients and 4-year follow-up. In a multicentre 2018 study, Siegel et al. [11] report a 67% success rate, while Kerrebroeck et al. [12] report a 71% success rate. Two important voiding parameters are frequency and urgency. Table 6 juxtapositions our present 60% improvement in frequency vs Siegel et al. [11] at 35% and Kerrebroeck et al. [12] at 34%. We found a 70% reduction (improvement) in urgency vs both previous groups' 33% and 9% reduction (improvement scores). Adverse events were also a critical comparison. In my practice and the literature [17] , adverse events commonly occur after falls or direct impact injuries, which lead to tine lead migration/ displacement or independent equipment failure and subsequent outpatient care or operative revisional surgery. While the three study groups ranged from 40% to 50%, we incurred a 12-24% rate of traditional adverse events. We theorise that, in our low-voltage placement of the tined lead, the functional proximity to the S 3 nerve may impart a more serviceable lead space, and the lead may migrate several more millimetres from the nerve before its function becomes clinically worsened, compared to leads placed at a higher voltage. For example, if proximity to the nerve is improved with a lower voltage motor response and the patient falls causing a tined lead migration of 2-10 mm, this small movement of the tined lead may still be functional. However, if the higher voltage response lead is 5-10 mm away, an additional 2-10 mm lead migration may cause a logarithmic decrease in the conductivity of the lead. The essential factors to entertain with our technique is that it is time efficient [ Table 1 , mean (SD) operative time 18.7 (6.73) min, P < 0.83] and likely cost effective without requiring additional training or equipment supplementation/purchase. This is a straightforward approach with statistically significant gains achieved Another investigative question is whether statistically significant improvements are achieved in patients' objective outcomes when the voltage to elicit a motor response is decreased from 3 to 2 to 1 V? Our MANOVA analysis ( Fig. 1 and Table 5) shows that once a motor response of 3-V is achieved compared to 2-or 1-V, there is no additional statistical improvement in most outcome measures (P < 0.19).
Three patient outcomes (Table 5 , each marked in bold print) were better in the 1-V cohorts vs either the 2-or 3-V groups; however, two of the three have nominal clinical importance. The PVR was better in the 1-V cohort with a mean improvement of 10 mL (P > 0.032). Nocturia improved by 0.17 voids/night (P < 0.04), but this is not clinically relevant.
The third parameter appears to hold special significance, in that patients with a 1-V motor response after Since 2017, Medtronic has been advocating the use of a lower voltage technique of ≤2 V, but as of March 2018, no evidence-based papers are available on Medline or PubMed, suggesting that this recommendation is opinion-based opposed to evidence-based. We contacted a Medtronic representative and requested information about the recommendation and were told that the <2-V recommendation is the opinion of their urology SNM consultant team.
We do not endorse this recommendation because of the >30% incidence of severe pelvic/perirectal pain and big toe movement, leaving patients hesitant to self-reprogram. With the above described ANOVA of the results, we show that once 3 V is achieved, no significant clinical improvements are attained by going lower with the motor response voltage -with the caveat that as you approach 1 V, the opportunity exists for severe pelvic pain and big toe movement with patient or physician reprogramming. Thus, 3 V is the safe, watershed moment for this low motor response technique, not 2 or 1 V.
Recently, our described technical concept may have encouraged Medtronic to sponsor a basic science study using lower voltages of 3, 2, and 1 V for motor responses in awake/ anaesthetised sheep [18] . We encourage both basic science and clinical research studies with lower voltage motor response for neuromodulation to other nerves to see whether a 30-40% improvement can also be attained with this simple technical adjustment. Could clinical improvements be attained for gastric paresis, lower back pain, pelvic pain, migraine headaches, and movement disorders? We can only speculate that this technique will offer clinical improvements in other conditions, as well.
Conclusion
Our observational, double cohort study of patients with OAB symptoms and urinary retention advocates the use of ≤3-V motor response in Stage 1 SNM. The ≤3-V technique has shown statistically significant improvements (P ≤ 0.05) in conversion rate, success rate, most voiding parameters, PGI-I, UDI-6, IIQ-7 questionnaires, adverse events, battery life, and annual reprogramming sessions with a mean follow-up approaching 10 years. We recommend a threshold of 3-V for motor response attainment to avoid potential problematic bellows and ipsilateral plantar flexion with small increments in voltage adjustments and because lower voltage imparts no statistically significant improvement in objective voiding parameters. Further randomised controlled trials must be conducted to verify our outcomes.
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